{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-24-000049","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.104865+00:00","generated_at":"2026-05-31T05:15:01.945295+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Moderna outlines 10 product approvals by 2027; cuts R&D spend, issues 2025 revenue guidance $2.5-3.5B","bullets":["Expects ten product approvals through 2027, including three respiratory vaccine submissions in 2024 (next-gen COVID, flu/COVID combo, RSV for high-risk adults).","Positive Phase 3 results for RSV vaccine in high-risk adults 18-59; sBLA filing planned in 2024 using Priority Review Voucher.","Cuts cumulative R&D spend for 2025-2028 by 20% to $16B; 2025 R&D guidance $4.2-4.5B; 2025 revenue guidance $2.5-3.5B.","Norovirus vaccine mRNA-1403 advances to Phase 3; INT melanoma Phase 3 substantially enrolled but FDA not supportive of accelerated approval.","Five pipeline programs discontinued; plans to break even on operating cash cost basis in 2028 with $6B revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-24-000049","json":"https://secwatch.observer/filing/0001682852-24-000049.json","markdown":"https://secwatch.observer/filing/0001682852-24-000049.md","text":"https://secwatch.observer/filing/0001682852-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000049/0001682852-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285224000049/mrna-20240912.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:15:01.945295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}